This is a Phase II single center, open-label, single arm study in patients with unresectable
thymic epithelial tumors (Masaoka stage III, IVA). Patients will be treated with
Pembrolizumab 200 mg, Docetaxel 75mg/m2, Cisplatin 75mg/m2 every 3 weeks for 3 cycles and
will be evaluated for the operability. Patients with R0 resection will receive pembrolizumab
200mg for 32 cycles. Patient who had R1 resection will receive radiation 52.8Gy/24Fx with
pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation
59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles. Patients who showed non-progressive
disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation
59.4Gy/27Fx with 200mg for 32 cycles. Otherwise patients are off the study.